-
1.发明申请公开(公告)号：US20190216894A1
公开(公告)日：2019-07-18
申请号：US16323950
申请日：2017-07-26
发明人： Yaling HAN , Xiaoxiang TIAN , Chenghui YAN , Quanyu ZHANG , Xiaolin ZHANG , Dan LIU
摘要： Described is the use of an E1A activating gene repressor (CREG) protein, in particular to a use of a CREG protein or an active fragment thereof in manufacture of a medicament for prevention and/or treatment of overweight, obesity, insulin resistance, hyperlipidemia and related diseases. Also described is the use of a recombinant vector or recombinant cell expressing a CREG protein or an active fragment thereof in manufacture of a medicament for prevention and/or treatment of overweight, obesity, insulin resistance, hyperlipidemia and related diseases.
-
公开(公告)号：US20200147172A1
公开(公告)日：2020-05-14
申请号：US16474903
申请日：2017-12-21
发明人： Yaling HAN , Quanyu ZHANG , Chenghui YAN , Xiaoxiang TIAN
IPC分类号： A61K38/17 , C12N15/85 , A61P3/10 , A01K67/027
摘要： The present invention relates to a use of cellular repressor of E1A-stimulated genes (CREG) protein, and in particular to a use of a CREG protein or an active fragment thereof in manufacture of a medicament for the prevention and/or treatment of a fatty liver disease and type 2 diabetes. The present invention also relates to a use of a recombinant vector or recombinant cell expressing a CREG protein or an active fragment thereof in manufacture of a medicament for the prevention and/or treatment of a fatty liver disease and type 2 diabetes. The invention also relates to a corresponding kit, such as a kit used for the predication and/or evaluation of therapeutic effect and prognosis of a fatty liver disease and type 2 diabetes.
-
搜索结果
2 条记录 (耗时 0.013 秒)
